Peptide Comparison Chart
Every compound referenced anywhere on this site — 34 in total — in one table: category, molecular class, primary mechanism, human clinical trial status, and FDA approval status for each. Each row links to a full page with sources and detail.
Last updated 24 August 2026. This is a research reference, not a buying guide or dosing chart — see the disclaimer below.
Weight Loss & Metabolic
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| Retatrutide | Synthetic triple agonist peptide | GIP + GLP-1 + glucagon receptors | Phase 3 (TRIUMPH) | Not approved (in trials) | Yes |
| 5-Amino-1MQ | Small molecule (not a peptide) | NNMT inhibition | Preclinical only | Not approved | Yes |
| Tirzepatide | Synthetic dual agonist peptide | GIP + GLP-1 receptors | Phase 3 (SURMOUNT) | Approved (Mounjaro, Zepbound) | Yes |
| Humanin | Mitochondrial-derived peptide | BAX binding / STAT3 signaling | Preclinical only | Not approved | Available to order |
| AOD-9604 | HGH C-terminus fragment | Isolated lipolytic activity | Phase IIb (failed) | Not approved | Available to order |
GHRH & Growth Hormone
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| CJC-1295 + Ipamorelin Blend | GHRH analog + ghrelin agonist blend | GHRH receptor + GHSR1a (dual) | No blend trial — see components | Not approved | Yes |
| Ipamorelin | Selective ghrelin-receptor agonist | GHSR1a | No completed human trial | Not approved | Yes |
| Tesamorelin | Modified GHRH(1-44) analog | GHRH receptor | Phase 3 trials | Approved (Egrifta, 2010) | Yes |
| Hexarelin | Dual-receptor secretagogue | GHSR1a + CD36 | Human GH-response data | Not approved | Available to order |
| Sermorelin | Unmodified GHRH(1-29) fragment | GHRH receptor | Historical human trials (pre-1990) | Formerly approved (Geref); discontinued 2008 | Available to order |
| GHRP-6 | Synthetic hexapeptide | Ghrelin receptor (GHSR1a), non-selective | Historical human trials (1980s–90s) | Not approved | Yes |
| Anamorelin | Orally active, non-peptide small molecule | Ghrelin receptor (GHSR1a) agonism | Phase 3 (ROMANA 1/2) | Not approved in US; approved in Japan (Adlumiz, 2021) | Not available |
Compare all four GH-axis compounds in detail →
Healing & Recovery
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide | Cytoprotective / angiogenic repair | No completed human trial | Not approved as a drug; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| TB-500 | Thymosin beta-4 fragment | Actin regulation / cell migration | No trial for TB-500 itself | Not approved as a drug; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| KLOW Blend | 4-peptide blend | Mixed (GHK-Cu, BPC-157, TB-500, KPV) | No blend trial — see components | Not approved | Yes |
| KPV | Tripeptide (alpha-MSH fragment) | Anti-inflammatory cytokine modulation | No completed human trial | Not approved as a drug; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| GHK-Cu | Copper-binding tripeptide | Collagen synthesis / tissue remodeling | Topical human data only | Not approved as a drug | Yes |
| TB-500 + BPC-157 Blend | 2-peptide blend | Combined tissue-repair mechanisms | No blend trial — see components | Not approved | Yes |
| ARA-290 | Erythropoietin-derived peptide | Innate repair receptor (EPOR/CD131) | Phase 2b | Not approved | Available to order |
| Thymosin Alpha-1 | Thymic peptide | TLR3/4/9 & NF-κB/IRF3 signaling | Phase 3 (primary endpoint not met) | Not FDA-approved; approved elsewhere (e.g. China, as Zadaxin) | Available to order |
| Vilon | Khavinson-lineage dipeptide | Proposed DNA-binding in thymic tissue | No human trial | Not approved | Available to order |
| Thymalin | Khavinson-lineage polypeptide complex | T-cell immune restoration (mechanism unclear) | Human cohort (Khavinson & Morozov, 2003) | Not FDA-approved; approved in Russia | Available to order |
Cognitive & Nootropic
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| Selank | Synthetic tuftsin analog | Anxiolytic-like / immunomodulatory | Human trials conducted | Not FDA-approved; approved in Russia | Yes |
| Semax | ACTH(4-10) analog | Neuroprotective / BDNF-linked | Human trials conducted | Not FDA-approved; approved in Russia; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| DSIP | Nonapeptide | Sleep architecture (mechanism unclear) | Human trials (1970s/80s) | Not approved; considered but not recommended for FDA's 503A compounding list, July 2026 | Available to order |
| Pinealon | Khavinson-lineage tripeptide | Proposed DNA-binding in cortical cells | No human trial | Not approved | Yes |
Longevity & Cellular Health
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| Epitalon | Synthetic tetrapeptide | Telomerase activity / pineal signaling | Human cohort (non-RCT) | Not approved as a drug; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| SS-31 | Mitochondria-targeted tetrapeptide | Cardiolipin binding | Phase 3 trials (Barth syndrome) | Approved (FORZINITY) | Yes |
| MOTS-c | Mitochondrial-derived peptide | AMPK / PGC-1α signaling | Phase 2a underway | Not approved as a drug; recommended (non-binding) for FDA's 503A compounding list, July 2026 | Yes |
| NAD+ | Coenzyme | Mitochondrial energy / sirtuin activation | Precursor trials only | Not approved | Yes |
| FOXO4-DRI | D-retro-inverso senolytic peptide | Disrupts FOXO4-p53 interaction | No human trial | Not approved | Available to order |
| Cartalax | Khavinson-lineage tripeptide | Proposed cartilage matrix gene activation | No human trial | Not approved | Available to order |
Sexual Health & Wellness
| Compound | Molecular Class | Primary Mechanism | Human Trial Status | FDA Status | From KYIN |
|---|---|---|---|---|---|
| PT-141 | Cyclic heptapeptide (melanocortin agonist) | Central MC4R agonism (arousal pathways) | Phase 3 (RECONNECT trials) | Approved (Vyleesi, 2019) | Available to order |
| Kisspeptin-10 | Decapeptide (KISS1 gene fragment) | KISS1R agonism (GnRH/LH release) | Human dose-response study (George et al., 2011) | Not approved | Available to order |
How to Read "Human Trial Status" and "FDA Status"
"Human Trial Status" summarizes the strongest human clinical evidence identified for each compound at the time of writing — it is not a safety or efficacy ranking. A compound with no completed human trial is not necessarily less safe than one that has been tested; it may simply be earlier in the research pipeline, or have a research base that has stayed preclinical for other reasons. "FDA Status" is a separate, narrower fact: whether the compound (or an approved drug version of it) currently holds FDA approval in the United States. The two columns can diverge — a compound can have extensive trial data and still not be FDA-approved, or hold approval in another country only. Full citations and context for every trial referenced here are on each compound's own page, linked from the table above.
Several rows also note a July 2026 development: the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP — as candidates for the Section 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally use. The committee narrowly recommended six of the seven (all but DSIP). This is a separate process from FDA drug approval: the vote is non-binding advice to the FDA, does not itself change any compound's legal status, and requires formal notice-and-comment rulemaking — typically 8–12 months or longer — before it could take effect. None of these compounds are FDA-approved drugs as a result of this vote. See our full write-up of the vote and sources →
Comparison chart questions
What does this chart include?
Every compound referenced anywhere on this site — the 20 peptides and compounds KYIN Peptides stocks, plus 14 additional compounds referenced in our research overviews that aren't part of the standard catalogue — most available to order, and one (Anamorelin) included for research reference only.
What does "human trial status" mean in the chart?
A short summary of the strongest human clinical evidence identified for that compound at the time of writing — ranging from full FDA approval, to a completed but negative trial, to preclinical/animal-only evidence. Full detail and citations are on each compound's own page.
What does the FDA Status column mean?
It shows whether that compound (or an approved drug version of it) has received FDA approval in the United States — separate from its general human trial status. Most compounds on this chart have not been evaluated or approved by the FDA; a small number have full or historical FDA approval, or approval in another country, which the column notes.
What does "recommended for the 503A compounding list" mean for BPC-157 and TB-500?
In July 2026, the FDA's Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the Section 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally use. This is a non-binding recommendation, not FDA drug approval — it does not change any compound's current legal status and would require formal rulemaking, typically 8–12 months or longer, before taking effect.
Is this chart updated?
It reflects the research and trial data documented across our site as of the last update date shown on this page. For the most current detail on any single compound, see its dedicated product or research page, which this chart links to directly.
Looking for specs and pricing?
Browse the full catalogue, or explore individual research pages linked from the chart above.